Structure

InChI Key JDUBGYFRJFOXQC-KRWDZBQOSA-N
Smile NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1
InChI
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H25ClN6O2
Molecular Weight 428.92
AlogP 2.15
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 6.0
Polar Surface Area 120.16
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Serine/threonine-protein kinase AKT inhibitor
Primary Target
AKT serine/threonine kinase 1
AKT serine/threonine kinase 2
AKT serine/threonine kinase 3

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Breast Neoplasms 3 D001943 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Adenocarcinoma 2 D000230 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials
Fallopian Tube Neoplasms 1 D005185 ClinicalTrials
Hereditary Breast and Ovarian Cancer Syndrome 1 D061325 ClinicalTrials
Uterine Cervical Neoplasms 1 D002583 ClinicalTrials
Ovarian Neoplasms 1 D010051 ClinicalTrials
Endometrial Neoplasms 1 D016889 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1143532-39-1
ChEMBL CHEMBL2325741
DrugBank DB12218
EPA CompTox DTXSID40150710
FDA SRS WFR23M21IE
Guide to Pharmacology 7709
PDB 0XZ
PubChem 25227436
SureChEMBL SCHEMBL390243
ZINC ZINC000043204023